Fintel reports that on October 2, 2023, Citigroup maintained coverage of Edwards Lifesciences (NYSE:EW) with a Buy recommendation.
Analyst Price Forecast Suggests 42.92% Upside
As of August 31, 2023, the average one-year price target for Edwards Lifesciences is 98.90. The forecasts range from a low of 75.75 to a high of $115.50. The average price target represents an increase of 42.92% from its latest reported closing price of 69.20.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Edwards Lifesciences is 5,940MM, an increase of 5.00%. The projected annual non-GAAP EPS is 2.59.
What is the Fund Sentiment?
There are 2348 funds or institutions reporting positions in Edwards Lifesciences. This is an increase of 270 owner(s) or 12.99% in the last quarter. Average portfolio weight of all funds dedicated to EW is 0.41%, an increase of 25.31%. Total shares owned by institutions increased in the last three months by 87.42% to 1,052,974K shares. 
The put/call ratio of EW is 0.51, indicating a bullish outlook.
What are Other Shareholders Doing?
BBCPX - Bridge Builder Core Plus Bond Fund holds 379,121K shares representing 62.36% ownership of the company. In it's prior filing, the firm reported owning 363,868K shares, representing an increase of 4.02%. The firm increased its portfolio allocation in EW by 6.19% over the last quarter.
Six Circles Trust - Six Circles Global Bond Fund holds 66,854K shares representing 11.00% ownership of the company. In it's prior filing, the firm reported owning 11,518K shares, representing an increase of 82.77%. The firm increased its portfolio allocation in EW by 491.63% over the last quarter.
Capital International Investors holds 27,015K shares representing 4.44% ownership of the company. In it's prior filing, the firm reported owning 25,759K shares, representing an increase of 4.65%. The firm increased its portfolio allocation in EW by 12.15% over the last quarter.
BBTBX - Bridge Builder Core Bond Fund holds 21,185K shares representing 3.48% ownership of the company. In it's prior filing, the firm reported owning 11,755K shares, representing an increase of 44.51%. The firm increased its portfolio allocation in EW by 83.68% over the last quarter.
DCFFX - Destinations Core Fixed Income Fund Class I holds 20,675K shares representing 3.40% ownership of the company.
Edwards Lifesciences Background Information
(This description is provided by the company.)
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. Edwards Lifesciences is driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
